Navigation Links
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
Date:7/1/2008

- Five-Year Defense Threat Reduction Agency Contract Will Support

Development of Bavituximab and Fully Human Equivalent as Potential

Broad-Spectrum Anti-Viral Agents -

TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced it has entered into a five-year contract worth up to $44.4 million to test and develop bavituximab and an equivalent fully human antibody as potential broad-spectrum treatments for viral hemorrhagic fever infections. The initial contract was awarded through the Transformational Medical Technologies Initiative (TMTI) of the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA).

Bavituximab is Peregrine's lead anti-phosphatidylserine (anti-PS) monoclonal antibody and is currently in clinical trials for the treatment of HCV infections and cancer. In preclinical animal models, bavituximab has demonstrated encouraging anti-viral activity as a potential treatment for viral hemorrhagic fevers. Peregrine's fully human anti-PS antibody, which will also be assessed under this contract, is currently in preclinical development.

Under the terms of the contact, DTRA funds are available to cover testing and development efforts totaling up to $22.3 million over a 24-month base period, with $5 million appropriated immediately for the current federal fiscal year ending September 30, 2008. The remainder of the $22.3 million in funding is expected to be appropriated over the remainder of the two-year base period ending June 29, 2010. The contract can be extended beyond the base
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
2. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
3. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
4. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
5. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
10. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
11. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Research and Markets ... Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism (SNP) genotyping ... SNPs in the genome of various species. SNPs are ... and analysis technology can analyze thousands of SNPs and ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... reason people over 60 are not donor candidates for ... with time, making the elderly prone to life-threatening infection ... team now has discovered a reason why. , "We ... of blood-forming cells to maintain blood production over time ... that could be restored for rejuvenation therapies," said Emmanuelle ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
Breaking Biology Technology:Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... Record Revenue and Operating Income, PLYMOUTH MEETING, Pa., Aug. ... Sunstone, or the ,Company,),today announced its financial results from the ... 10Q today., Highlights -- Record revenues for ... $47.7 million -- Non-GAAP operating income ...
... enforcement officials may some day have a new ally - ... virtually all of the major threat agents that could be ... development by a team of Lawrence Livermore National Laboratory (LLNL) ... and field experiments. , In their latest advance, the team ...
... devised an inexpensive way to produce plastic sheets containing ... the sun and other sources. The technology, developed at ... the first step toward a solar energy collector that ... to convert the energy into usable electricity still need ...
Cached Biology Technology:BMP Sunstone Reports Second Quarter 2008 Financial Results 2BMP Sunstone Reports Second Quarter 2008 Financial Results 3BMP Sunstone Reports Second Quarter 2008 Financial Results 4BMP Sunstone Reports Second Quarter 2008 Financial Results 5BMP Sunstone Reports Second Quarter 2008 Financial Results 6BMP Sunstone Reports Second Quarter 2008 Financial Results 7BMP Sunstone Reports Second Quarter 2008 Financial Results 8BMP Sunstone Reports Second Quarter 2008 Financial Results 9BMP Sunstone Reports Second Quarter 2008 Financial Results 10BMP Sunstone Reports Second Quarter 2008 Financial Results 11Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances 2Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances 3Flexible nanoantenna arrays capture abundant solar energy 2Flexible nanoantenna arrays capture abundant solar energy 3
(Date:7/31/2014)... scientists from Spain, France, and the U.S. has ... the oldest definitive member of the tribe Omaliini ... discovery and description were made possible through the ... technique, which allows the detailed study of otherwise ... is described in the journal Annals of ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
(Date:7/31/2014)... exposure to loud noise alters how the brain ... speech sounds, according to neuroscientists at The University ... published this week in Ear and Hearing ... noise-induced hearing loss affects the brain,s recognition of ... all corners of the population, affecting an estimated ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2
... Electrical noise, like the crackle heard on AM radio when ... electronic devices. But within cells, a similar kind of biochemical ... another, according to a new study led by a UT ... professor of pharmacology, said his research and that of his ...
... asparaginase fails to help cure some children with acute ... in the bone marrow counteract the effect of that ... Hospital. , The researchers showed that mesenchymal cells ... leukemic cells by releasing large amounts of asparagine, an ...
... understanding of how tool use has evolved among primates, ... some conditions, are capable of habitually fashioning and using ... Jill Pruetz of Iowa State University and Paco Bertolani ... the journal Current Biology on February 22nd. , Chimpanzees ...
Cached Biology News:Cells use 'noise' to make cell-fate decisions 2Cells use 'noise' to make cell-fate decisions 3Leukemic cells find safe haven in bone marrow 2Leukemic cells find safe haven in bone marrow 3Chimpanzees found to use tools to hunt mammalian prey 2
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Naphthol Blue Black, CI 20470...
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Biology Products: